Literature DB >> 16406853

Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol.

Dong Xu1, Qinghua Lu, Xun Hu.   

Abstract

P-glycoprotein accounts for the most intrinsic and acquired cancer multidrug resistance. To inhibit the expression of P-glycoprotein is one of the effective ways to reverse cancer drug resistance. Honokiol, a naturally occurring compound, has been demonstrated to combat cancer through mechanisms including inhibition of angiogenesis and induction of apoptosis. Here, we show that honokiol down-regulated the expression of P-glycoprotein at mRNA and protein levels in MCF-7/ADR, a human breast MDR cancer cell line. The down-regulation of P-glycoprotein was accompanied with a partial recovery of the intracellular drug accumulation, and of the sensitivities toward adriamycin. This study reveals a novel function of honokiol as an anti-cancer agent.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16406853     DOI: 10.1016/j.canlet.2005.11.031

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  28 in total

1.  Discovering active compounds from mixture of natural products by data mining approach.

Authors:  Yi Wang; Yecheng Jin; Chenguang Zhou; Haibin Qu; Yiyu Cheng
Journal:  Med Biol Eng Comput       Date:  2008-03-05       Impact factor: 2.602

2.  Self-assembled hydrophobic honokiol loaded MPEG-PCL diblock copolymer micelles.

Authors:  MaLing Gou; XiuLing Zheng; Ke Men; Juan Zhang; BiLan Wang; Lei Lv; XiuHong Wang; YinLan Zhao; Feng Luo; LiJuan Chen; Xia Zhao; YuQuan Wei; ZhiYong Qian
Journal:  Pharm Res       Date:  2009-07-01       Impact factor: 4.200

3.  Modulation of P-glycoprotein expression by triptolide in adriamycin-resistant K562/A02 cells.

Authors:  Hao Li; Lulu Hui; Wenlin Xu; Huiling Shen; Qiaoyun Chen; Lulu Long; Xiaolan Zhu
Journal:  Oncol Lett       Date:  2011-11-30       Impact factor: 2.967

4.  Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer.

Authors:  Junqing Chen; Wei Tian; Hongke Cai; Haifei He; Yongchuan Deng
Journal:  Med Oncol       Date:  2011-11-19       Impact factor: 3.064

5.  Increasing the cytotoxicity of doxorubicin in breast cancer MCF-7 cells with multidrug resistance using a mesoporous silica nanoparticle drug delivery system.

Authors:  Xin Wang; Zhaogang Teng; Haiyan Wang; Chunyan Wang; Ying Liu; Yuxia Tang; Jiang Wu; Jin Sun; Hai Wang; Jiandong Wang; Guangming Lu
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

6.  Characterization of the cell growth inhibitory effects of a novel DNA-intercalating bipyridyl-thiourea-Pt(II) complex in cisplatin-sensitive and -resistant human ovarian cancer cells.

Authors:  Gaetano Marverti; Alessio Ligabue; Monica Montanari; Davide Guerrieri; Matteo Cusumano; Maria Letizia Di Pietro; Leonarda Troiano; Elena Di Vono; Stefano Iotti; Giovanna Farruggia; Federica Wolf; Maria Giuseppina Monti; Chiara Frassineti
Journal:  Invest New Drugs       Date:  2009-10-16       Impact factor: 3.850

Review 7.  Honokiol, a multifunctional antiangiogenic and antitumor agent.

Authors:  Levi E Fried; Jack L Arbiser
Journal:  Antioxid Redox Signal       Date:  2009-05       Impact factor: 8.401

8.  Hedyotis diffusa Willd overcomes 5-fluorouracil resistance in human colorectal cancer HCT-8/5-FU cells by downregulating the expression of P-glycoprotein and ATP-binding casette subfamily G member 2.

Authors:  Qiongyu Li; Xiangfeng Wang; Aling Shen; Yuchen Zhang; Youqin Chen; Thomas J Sferra; Jiumao Lin; Jun Peng
Journal:  Exp Ther Med       Date:  2015-09-22       Impact factor: 2.447

9.  Curcumin prevents induced drug resistance: a novel function?

Authors:  Dong Xu; Wei Tian; Hong Shen
Journal:  Chin J Cancer Res       Date:  2011-09       Impact factor: 5.087

10.  Troglitazone reverses the multiple drug resistance phenotype in cancer cells.

Authors:  Gerald F Davies; Bernhard H J Juurlink; Troy A A Harkness
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.